Drugs for Neglected Diseases initiative model of drug development for neglected diseases: Current status and future challenges

Future Medicinal Chemistry

Volumn 3, Issue 11, 2011, Pages 1361-1371

  Ioset, Jean Robert ^a   Chang, Shing ^a  

^a Drugs for Neglected Diseases Initiative DNDi   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICAN TRYPANOSOMIASIS; ARTICLE; DRUG INDUSTRY; DRUG REPOSITIONING; DRUG RESEARCH; MALARIA; MODEL; NEGLECTED DISEASE; NON PROFIT ORGANIZATION; PATENT; PRIORITY JOURNAL; VISCERAL LEISHMANIASIS;

DRUG DISCOVERY; DRUG INDUSTRY; MODELS, ORGANIZATIONAL; NEGLECTED DISEASES; PROGRAM DEVELOPMENT; PUBLIC-PRIVATE SECTOR PARTNERSHIPS;

EID: 80052396428     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.11.102     Document Type: Article

References (22)

1. Feasey N, Wansbrough-Jones M, Mabey DC, Solomon AW. Neglected tropical diseases. Br. Med. Bull. 93,179-200 (2010).
2. Hotez PJ, Kamath A. Neglected tropical diseases in suβsaharan Africa: review of their prevalence, distribution, and disease burden. PLoS Negl. Trop. Dis. 3 (8), e412 (2009).
3. Hotez PJ, Pécoul B. 'Manifesto' for advancing the control and elimination of neglected tropical diseases. PLoS Negl. Trop. Dis. 4(5), e718 (2010).
4. Conteh L, Engels T, Molyneux DH. Socioeconomic aspects of neglected tropical diseases. Lancet 375(9710), 239-247 (2010).
5. Mathers CD, Ezzati M, Lopez AD. Measuring the burden of neglected tropical diseases: the global burden of disease framework. PLoS Negl. Trop. Dis. 1(2), e114, (2007).
6. Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, Ford N. Drug development for neglected diseases. Lancet 359(9324), 2188-2194 (2002).
7. Chirac P, Torreele E. Global framework on essential health R&D. Lancet 367(9522), 1560-1561 (2006). (Pubitemid 43674241)
8. Pécoul B. New drugs for neglected diseases: from pipeline to patients. PLoS Med. 1(1), e6 (2004).
9. Nwaka S, Ridley RG. Virtual drug discovery and development for neglected diseases through public-private partnerships. Nat. Rev. Drug Discov. 2(11), 919-928 (2003). (Pubitemid 37419900)
10. Croft SL. Public-private partnership: from there to here. Trans. R. Soc. Trop. Med. Hyg. 99(Suppl. 1), S9-S14 (2005). (Pubitemid 41179260)
11. Preziosi P. Science, pharmacoeconomics and ethics in drug R&D: a sustainable future scenario? Nat. Rev. Drug Discov. 3(6), 521-526 (2004). (Pubitemid 38807534)
12. Don R, Chatelain E. Drug discovery for neglected diseases: view of a public-private partnership. In:Antiparasitic and Antibacterial Drug Discovery: From Molecular Targets to Drug Candidates . Selzer PM (Ed.).Wiley-VCH GmbH & Co., Weinheim, Germany 33-43 (2009).
13. Jacobs RT, Plattner JJ, Nare B et al. Benzoxaboroles: a new class of potential drugs for human African trypanosomiasis. Future Med. Chem. 3(10), 1259-1278 (2011).
14. Curry S, Brown R. The target product profile as a planning tool in drug discovery research. Pharmatech 67-71 (2003).
15. Bost, F, Jacobs RT, Kowalczyk P. Informatics for neglected diseases collaborations Curr. Opin. Drug Discov. Devel. 13(3), 286-296 (2010).
16. Frearson JA, Brand S, McElroy SP et al. N-myristoyltransferase inhibitors as new leads to treat sleeping sickness. Nature 464(7289), 728-732 (2010).
17. Holloway GA, Charman WN, Fairlamb AH et al. Trypanothione reductase high-throughput screening campaign identifies novel classes of inhibitors with antiparasitic activity. Antimicrob. Agents Chemother. 53(7), 2824-2833 (2009).
18. Torrie LS, Wyllie S, Spinks D et al. Chemical validation of trypanothione synthetase: a potential drug target for human trypanosomiasis J. Biol. Chem. 284(52), 36137-36145 (2009).
19. Sykes ML, Avery VM. Development of an Alamar Blue™ viability assay in 384-well format for high throughput whole cell screening of Trypanosoma brucei brucei bloodstream form strain 427 Am. J. Trop. Med. Hyg. 81(4), 665-674 (2009).
20. Chatelain E, Ioset J-R. Drug discovery and development for neglected diseases: the DNDi model. Drug Des. Devel. Ther. 16(5), 175-181 (2011).
21. Torreele E, Bourdin Trunz B, Tweats D et al Fexinidazole - a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl. Trop. Dis. 4(12), e923 (2010).
22. Jennings FW, Urquhart GM. The use of the 2 substituted 5-nitroimidazole, Fexinidazole (Hoe 239) in the treatment of chronic T. brucei infections in mice. Z. Parasitenkd 69, 577-581 (1983). (Pubitemid 13004457)